Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 2/20 | 0.36 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 4/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.34 |
| ▸ | BTK | Q06187 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.33 |
| ▸ | GHSR | Q92847 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | MGLL | Q99685 | 1/20 | 0.32 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16670702 | 0.86 | ABL1 (0.38) | ABL1HCRTR1HCRTR2BTKGHSR | |
| SCHEMBL20998606 | 0.84 | TDP1 (0.39) | PTGER4PTGER2ABL1HCRTR1HCRTR2 | |
| SCHEMBL20998605 | 0.80 | TDP1 (0.41) | PTGER4PTGER2ABL1BTKTDP1 | |
| SCHEMBL16670687 | 0.78 | BTK (0.44) | BTK | |
| SCHEMBL16671416 | 0.78 | CKS1B (0.42) | ABL1BTK | |
| SCHEMBL16670224 | 0.77 | BTK (0.43) | HCRTR1HCRTR2BTKTDP1 | |
| SCHEMBL16670236 | 0.77 | BTK (0.42) | ABL1BTKGHSRCHRM1KMT2A | |
| SCHEMBL16671584 | 0.77 | BTK (0.44) | BTK | |
| SCHEMBL20998624 | 0.76 | TDP1 (0.46) | HCRTR1HCRTR2TDP1 | |
| SCHEMBL28106063 | 0.75 | CHRNB2 (0.47) | TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10329270-B2 | Heteroaryl compounds as BTK inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2019-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10329270-B2 | Heteroaryl compounds as BTK inhibitors and uses thereof | BTK, SYK, LCK | PTGER4 2926/4885PTGER2 2732/4885ABL1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.